Boston Scientific Co. (NYSE:BSX) Shares Sold by Meiji Yasuda Life Insurance Co

Meiji Yasuda Life Insurance Co reduced its position in shares of Boston Scientific Co. (NYSE:BSX) by 7.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 183,943 shares of the medical equipment provider’s stock after selling 14,429 shares during the period. Boston Scientific accounts for about 0.3% of Meiji Yasuda Life Insurance Co’s holdings, making the stock its 26th biggest holding. Meiji Yasuda Life Insurance Co’s holdings in Boston Scientific were worth $16,430,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Parnassus Investments LLC raised its stake in shares of Boston Scientific by 0.7% in the 4th quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider’s stock valued at $1,327,000 after acquiring an additional 97 shares during the period. Evergreen Capital Management LLC increased its holdings in Boston Scientific by 1.7% in the 4th quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider’s stock valued at $565,000 after purchasing an additional 106 shares during the last quarter. PDS Planning Inc raised its position in Boston Scientific by 1.5% in the fourth quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider’s stock valued at $668,000 after purchasing an additional 113 shares during the period. Adero Partners LLC lifted its stake in Boston Scientific by 3.3% during the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider’s stock worth $334,000 after purchasing an additional 120 shares in the last quarter. Finally, Tradition Wealth Management LLC boosted its position in shares of Boston Scientific by 2.2% during the fourth quarter. Tradition Wealth Management LLC now owns 5,510 shares of the medical equipment provider’s stock worth $492,000 after buying an additional 121 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Trading Up 0.3 %

NYSE BSX opened at $103.16 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $98.51 and a 200 day moving average price of $95.24. The stock has a market capitalization of $152.59 billion, a P/E ratio of 82.53, a P/E/G ratio of 2.79 and a beta of 0.73. Boston Scientific Co. has a 52-week low of $70.97 and a 52-week high of $107.17.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business’s revenue was up 20.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.56 EPS. Equities research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 6,528 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $104.97, for a total transaction of $685,244.16. Following the completion of the transaction, the executive vice president now directly owns 26,449 shares in the company, valued at approximately $2,776,351.53. This trade represents a 19.80 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares of the company’s stock, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 138,009 shares of company stock valued at $14,407,381 in the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BSX. Truist Financial boosted their price objective on Boston Scientific from $113.00 to $117.00 and gave the company a “buy” rating in a report on Thursday, April 24th. Evercore ISI increased their price target on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an “outperform” rating in a research report on Thursday, April 24th. Royal Bank of Canada lifted their price objective on shares of Boston Scientific from $116.00 to $120.00 and gave the company an “outperform” rating in a report on Thursday, April 24th. Citigroup upped their target price on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Finally, Stifel Nicolaus boosted their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Twenty-three analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $114.52.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.